DANA-FARBER CANCER INSTITUTE

Breast cancer patients in a remote weight-loss intervention program lost an average of 4.7% of their baseline body weight after one year, while control group participants gained 1% of their baseline weight.

Cue Biopharma has dosed the first patient with CUE-102 in a Phase 1b investigator-sponsored trial for recurrent glioblastoma multiforme at Dana-Farber Cancer Institute.

Researchers at Dana-Farber Cancer Institute have developed SWIFT-seq, a blood test that uses single-cell sequencing to profile circulating tumor cells and could replace painful bone marrow biopsies for multiple myeloma diagnosis and monitoring.

Dana-Farber Cancer Institute, Boston Children's Hospital, and Broad Clinical Labs have formed BrightSeq, a collaborative initiative to develop clinical molecular testing assays specifically for pediatric cancers.

A multi-institutional study found that 42% of ovarian cancer patients who achieved clinical remission after first-line therapy still harbored minimal residual disease (MRD) detectable through second-look laparoscopy.

The third annual Bridging the Gaps in Lung Cancer consensus meeting brings together approximately 30 global experts to identify and address unresolved clinical challenges in lung cancer management.

Chromophobe renal cell carcinoma (ChRCC) demonstrates an immune-cold tumor microenvironment with significantly reduced CD8+ T-cell infiltration compared to clear cell RCC, explaining poor immunotherapy responses.

Dana-Farber researchers developed NeoVaxMI, an improved version of their personalized cancer vaccine that demonstrated enhanced immune responses in all nine melanoma patients tested.

Sunstone Therapies has conducted over 150 MDMA sessions through expanded access programs, demonstrating the drug's relational properties that facilitate therapeutic conversations and empathy.

The TRUST trial, the first phase III randomized study comparing surgical timing in advanced ovarian cancer, demonstrated statistically significant improvement in progression-free survival with primary cytoreductive surgery versus interval surgery (22.1 vs 19.7 months, HR=0.80, P=.018).